Crinetics Pharmaceuticals (NASDAQ:CRNX) reported quarterly losses of $(0.96) per share which missed the analyst consensus estimate of $(0.92) by 4.35 percent. This is a 4.95 percent increase over losses of $(1.01) per share from the same period last year.
Crinetics Pharmaceuticals Q3 2024 GAAP EPS $(0.96) Misses $(0.92) Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated